MEDICAL FEE DISPUTE RESOLUTION FINDINGS AND DECISION

GENERAL INFORMATION

Requestor Name

Memorial Compounding Pharmacy

MFDR Tracking Number

M4-17-0666-01

MFDR Date Received

November 7, 2016

Respondent Name

Preferred Professional Ins

Carrier's Austin Representative

Box Number 01

REQUESTOR'S POSITION SUMMARY

<u>Requestor's Position Summary:</u> "Memorial Compounding Pharmacy has made numerous attempts to have the attached bills processed. Broadspire has yet to approve or deny our bills. Broadspire has not sent Memorial Compounding Pharmacy any type of correspondence, EOB, or payments on any of the attached bills. Proof of timely filing is attached along with all the attempts to have the bills processed. We are not requesting Medical Fee Dispute Resolution."

Amount in Dispute: \$3,046.65

RESPONDENT'S POSITION SUMMARY

Respondent's Position Summary: "Payment has been disputed for dates of service 7/15/16 and 8/29/16 as the prescriptions were not preauthorized. The remaining dates of 1/29/16, 2/15/16 and 3/16/16 have been paid."

Response Submitted by: Broadspire

SUMMARY OF FINDINGS

Dates of Service	Disputed Services	Amount In Dispute	Amount Due
January 29, 2016 through August 29, 2016	Pharmacy Services - Compounds	\$3,046.65	\$1,218.66

FINDINGS AND DECISION

This medical fee dispute is decided pursuant to Texas Labor Code §413.031 and applicable rules of the Texas Department of Insurance, Division of Workers' Compensation.

Background

- 1. 28 Texas Administrative Code §133.307 sets out the procedures for resolving medical fee disputes.
- 2. 28 Texas Administrative Code §134.502 sets out the procedures for pharmaceutical benefits.
- 3. 28 Texas Administrative Code §134.503 sets out the fee guidelines for pharmaceutical services.
- 4. 28 Texas Administrative Code §134.530 sets out the closed formulary requirements for claims not subject to certified networks.

- 5. The insurance carrier reduced payment for the disputed services with the following claim adjustment codes:
 - 39 Denied Medication Not Authorized

<u>Issues</u>

- 1. Is Broadspire's reason for denial of payment supported?
- 2. Is Memorial Compounding Pharmacy entitled to reimbursement for the compound in question?

Findings

1. Memorial Compounding Pharmacy is seeking reimbursement of \$3,046.65 for a compound dispensed between January 29, 2016 and August 29, 2016. Broadspire denied the disputed compound with claim adjustment reason code 39 – "Denied – Medication Not Authorized."

28 Texas Administrative Code §134.530(b)(2) states that preauthorization is only required for:

- drugs identified with a status of "N" in the current edition of the ODG Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates;
- any compound that contains a drug identified with a status of "N" in the current edition of the ODG
 Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and
 any updates; and
- any investigational or experimental drug for which there is early, developing scientific or clinical evidence demonstrating the potential efficacy of the treatment, but which is not yet broadly accepted as the prevailing standard of care as defined in Labor Code §413.014(a).

The division finds that the compound in question does not include a drug identified with a status of "N" in the current edition of the ODG, *Appendix A*. Broadspire failed to articulate any arguments to support its denial for preauthorization. Therefore, the division concludes that the compound in question did not require preauthorization and Broadspire's denial of payment for this reason is not supported. Therefore, the disputed compound will be reviewed for reimbursement.

- 2. 28 Texas Administrative Code §134.503 applies to the compounds in dispute and states, in pertinent part:
 - (c) The insurance carrier shall reimburse the health care provider or pharmacy processing agent for prescription drugs the lesser of:
 - (1) the fee established by the following formulas based on the average wholesale price (AWP) as reported by a nationally recognized pharmaceutical price guide or other publication of pharmaceutical pricing data in effect on the day the prescription drug is dispensed:
 - (A) Generic drugs: ((AWP per unit) x (number of units) x 1.25) + \$4.00 dispensing fee per prescription = reimbursement amount;
 - (B) Brand name drugs: ((AWP per unit) x (number of units) x 1.09) + \$4.00 dispensing fee per prescription = reimbursement amount;
 - (C) When compounding, a single compounding fee of \$15 per prescription shall be added to the calculated total for either paragraph (1)(A) or (B) of this subsection; or
 - (2) notwithstanding §133.20(e)(1) of this title (relating to Medical Bill Submission by Health Care Provider), the amount billed to the insurance carrier by the:
 - (A) health care provider; or
 - (B) pharmacy processing agent only if the health care provider has not previously billed the insurance carrier for the prescription drug and the pharmacy processing agent is billing on behalf of the health care provider.

The compound in dispute was billed by listing each drug included in the compound and calculating the charge for each drug separately as required by 28 Texas Administrative Code §134.502(d)(2). Each ingredient is listed below with its corresponding reimbursement amount as applicable.

Date of Service	Ingredient	NDC &	Price/	Total	AWP Formula	Billed Amt	Lesser of
		Туре	Unit	Units	§134.503(c)(1)	§134.503 (c)(2)	(c)(1) and (c)(2)
January 29, 2016	Baclofen 100%	38779038809 Generic	\$35.63	60	\$2,676.25	\$609.33	\$609.33
February 15, 2016	Baclofen 100%	38779038809 Generic	\$35.63	60	\$2,676.25	\$609.33	\$609.33
March 16, 2016	Baclofen 100%	38779038809 Generic	\$35.63	60	\$2,676.25	\$609.33	\$609.33
July 15, 2016	Compounding fee	NA	\$15.00	1		\$15.00	\$15.00
July 15, 2016	Versapro Cream	38779252903 Generic	\$3.20	40.8	\$147.01	\$102.00	\$102.00
July 15, 2016	Ethoxy Diglycol	38779190301 Generic	\$0.342	4.2	\$5.71	\$1.44	\$1.44
July 15, 2016	Amitriptyline HCL	38779018904 Generic	\$18.24	1.8	\$49.60	\$31.63	\$31.63
July 15, 2016	Bupivacaine HCL	38779052405 Generic	\$45.60	1.2	\$61.00	\$48.02	\$48.02
July 15, 2016	Gabapentin USP	38779246109 Generic	\$59.85	3.6	\$303.25	\$188.10	\$188.10
July 15, 2016	Amantadine HCL	38779041105 Generic	\$24.225	3	\$94.84	\$38.46	\$38.46
July 15, 2016	Baclofen	38779038809 Generic	\$35.63	5.4	\$226.69	\$184.68	\$184.68
August 29, 2016	Compounding fee	NA	\$15.00	1		\$15.00	\$15.00
August 29, 2016	Versapro Cream	38779252903 Generic	\$3.20	40.8	\$147.01	\$102.00	\$102.00
August 29, 2016	Ethoxy Diglycol	38779190301 Generic	\$0.342	4.2	\$5.71	\$1.44	\$1.44
August 29, 2016	Amitriptyline HCL	38779018904 Generic	\$18.24	1.8	\$49.60	\$31.63	\$31.63
August 29, 2016	Bupivacaine HCL	38779052405 Generic	\$45.60	1.2	\$61.00	\$48.02	\$48.02
August 29, 2016	Gabapentin USP	38779246109 Generic	\$59.85	3.6	\$303.25	\$188.10	\$188.10
August 29, 2016	Amantadine HCL	38779041105 Generic	\$24.225	3	\$94.84	\$38.46	\$38.46
August 29, 2016	Baclofen	38779038809 Generic	\$35.63	5.4	\$226.69	\$184.68	\$184.68
						Total	\$3,046.65

The carrier provided evidence of payment for dates of service January 29, 2016 in the amount of \$609.33, February 16, 2016 in the amount of \$609.33 and March 16, 2016 in the amount of \$609.33 for a total payment of \$1,827.99. This amount was reduced from the ordered amount below.

The total reimbursement is therefore \$3,046.65. The carrier previously paid \$1,827.99. The remaining balance is \$1,218.66. This amount is recommended.

Conclusion

For the reasons stated above, the Division finds that the requestor has established that additional reimbursement is due. As a result, the amount ordered is \$1,218.66.

ORDER

Based on the submitted information, pursuant to Texas Labor Code Section 413.031 and 413.019 (if applicable), the division has determined the requestor is entitled to additional reimbursement for the disputed services. The division hereby ORDERS the respondent to remit to the requestor \$1,218.66, plus applicable accrued interest per 28 Texas Administrative Code §134.130, due within 30 days of receipt of this order.

		December 21, 2017
Signature	Medical Fee Dispute Resolution Officer	Date

Authorized Signature

YOUR RIGHT TO APPEAL

Either party to this medical fee dispute has a right to seek review of this decision in accordance with Rule §133.307, effective May 31, 2012, *37 Texas Register 3833*, applicable to disputes filed on or after June 1, 2012.

A party seeking review must submit a **Request to Schedule a Benefit Review Conference to Appeal a Medical Fee Dispute Decision** (form **DWC045M**) in accordance with the instructions on the form. The request must be received by the division within **twenty** days of your receipt of this decision. The request may be faxed, mailed or personally delivered to the division using the contact information listed on the form or to the field office handling the claim.

The party seeking review of the MFDR decision shall deliver a copy of the request to all other parties involved in the dispute at the same time the request is filed. **Please include a copy of the** *Medical Fee Dispute Resolution Findings* **and** *Decision* together with any other required information specified in 28 Texas Administrative Code §141.1(d).

Si prefiere hablar con una persona en español acerca de ésta correspondencia, favor de llamar a 512-804-4812.